Friday, July 10, 2026
🇺🇸 FDA

pharma · Relapsed or Refractory Multiple Myeloma (RRMM) · Relapsed and/or Refractory Multiple Myeloma

Celgene

Celgene Europe Limited

Celgene Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Relapsed or Refractory Multiple Myeloma (RRMM), Relapsed and/or Refractory Multiple Myeloma, Multiple Myeloma, Moderate

Website Investor relations
Summit, USA HQ
2,104 Employees
EMA registrant Type
Programs 45 Drugs 91 Patents 0 Trial starts 45 Last 12 months
Company details
Status
Public
HQ
Summit, USA
Employees
2,104
Programs
45
Drugs
91
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Quick answer

Celgene Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Relapsed or Refractory Multiple Myeloma (RRMM), Relapsed and/or Refractory Multiple Myeloma, Multiple Myeloma, Moderately to Severely Active Crohn's Disease, extensive stage small cell lung cancer. NovaPharmaNews links 45 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (19), phase 2 (17), phase 1 (9).

Company snapshot

We have merged with Bristol Myers Squibb creating a leading biopharma company, ideally positioned to discover, develop and deliver innovative medicines for patients fighting serious diseases. Visit www.bms.com to continue to learn more about our work to produce the next generation of medicines to treat cancer and other serious diseases. For more information on the acquisition, see our press releas

  • 45 active pipeline program(s) linked via ClinicalTrials.gov.
  • 45 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Celgene. Not investment advice.

Top assets

View drugs (80) View projects (45)

Lead pipeline drugs

Active clinical programs

  • ACE-536-LTFU-001 myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibrosis (MF)
    Phase 3
  • ACE-536-MF-002 Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)
    Phase 3
  • BB2121-MM-003 Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.
    Phase 3
  • CA0561060 Myelodysplastic syndrome
    Phase 3

Momentum

Proprietary activity score for Celgene.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 7 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Recent activity

Latest pipeline, patent, and corporate events for Celgene.

  1. Clinical update

    CA1190002 — Phase 1

  2. Clinical update

    RPC01-3203 — Phase 3

  3. Clinical update

    IM047-023 — Phase 3

  4. Clinical update

    FEDR-MF-002 — Phase 3

  5. Clinical update

    CC-92480-MM-001 — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Celgene?

    Celgene Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Relapsed or Refractory Multiple Myeloma (RRMM), Relapsed and/or Refractory Multiple Myeloma, Multiple Myeloma, Moderately to Severely Active Crohn's Disease, extensive stage small

  • Is Celgene publicly traded?

    Celgene appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Celgene develop or market?

    We link 91 drug profile(s) where Celgene is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/celgene-europe-limited#company-drugs.

  • What are the latest developments for Celgene?

    In the last 12 months our linked public records show 45 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Celgene focus on?

    Celgene focuses on Relapsed or Refractory Multiple Myeloma (RRMM), Relapsed and/or Refractory Multiple Myeloma, Multiple Myeloma based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
76
Oncology
7
Neurology
2
Immunology
1

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.